Global specialty pharmaceutical company focusing on central nervous system (CNS), gastrointestinal (GI), and renal diseases. Based in Chineham, England. (Nasdaq: SHPGY)
Research and development and production of new porphyrinic photosensitizers for photodynamic cancer therapy and other applications in collaboration with partners from institutes and universities throughout Europe.
Early stage drug discovery opportunities, research expertise and facilities, and intellectual property available for licensing from the Strathclyde Institute for Drug Research, University of Strathclyde, Glasgow, Scotland.
Joining mailing list will entitle you
to receive occasional emails informing you of news and
updates to the site and any special offers that may be
of interest to you.